391
Participants
Start Date
February 28, 2013
Primary Completion Date
May 31, 2018
Study Completion Date
August 31, 2018
Tesamorelin for injection
Daily 2 mg subcutaneous injections of Tesamorelin
Ricky K. Hsu, MD, PC, New York
University at Buffalo, State University of NY, Erie County Medical Center, Buffalo
Reading Hospital and Medical Center, West Reading
Dupont Circle Physician's Group, Washington D.C.
Capital Medical Associates, PC, Washington D.C.
Absolute Care Medical Center, Atlanta
Orange County Health Department, Orlando
Orange County Health Department, Orlando
The Kinder Medical Group-AHF, Miami
Rowan Tree Medical, P.A., Wilton Manors
Gary J. Richmond, M.D., PA, Fort Lauderdale
Summa Health Care System, Akron
Northstar Medical Center, Chicago
Southern Illnois University School of Medicine, Springfield
Southhampton Clinical Research, Inc. d.b.a. Central West Clinical Research, St Louis
Southampton Healthcare, Inc., St Louis
Virginia Mason Medical Center, Tulsa
Dallas VA Medical Center, Dallas
University of Texas Southwestern Medical Center at Dallas, Dallas
St. Hope Foundation, Inc., Bellaire
University of California CARE Clinic, Los Angeles, Los Angeles
Tower Infectious Diseases Medical Associates, Los Angeles
Oasis Clinic, Los Angeles
Pacific Coast Medical Group, Fountain Valley
Franco Felizarta, MD, Bakersfield
VAMC, Infectious Disease Section 111W, San Francisco
Virginia Mason Medical Center, Seattle
Massachusetts General Hospital, Boston
The Researth Institute, Springfield
Be Well Medical Center, P.C, Berkley
South Jersey Unfectious Disease, Somers Point
Lead Sponsor
Theratechnologies
INDUSTRY